Retrospective analysis of treatments with recombinant FSH and recombinant LH versus human menopausal gonadotropin in women with reduced ovarian reserve
- PMID: 28871409
- PMCID: PMC5714826
- DOI: 10.1007/s10815-017-1034-z
Retrospective analysis of treatments with recombinant FSH and recombinant LH versus human menopausal gonadotropin in women with reduced ovarian reserve
Abstract
Purposes: The aim of this study is to determine whether a clinical advantage is gained with use of LH in combination with FSH or as a component of human menopausal gonadotropin (hMG) to achieve optimal ovarian stimulation.
Methods: In this study, we compared retrospectively two regimens, r-FSH/r-LH and hMG, for the treatment of women with reduced ovarian reserve, identified as subjects with antral follicle count (AFC) < 11 and AMH ≤ 1.1 ng/ml.
Results: Overall, the clinical pregnancy per started cycle was higher in the r-FSH/r-LH group (12.5 vs. 8.1%, P < 0.02), while implantation (11.1 vs. 9.5%) and miscarriage rates (29.9 vs. 35.9%) were comparable. Data were further analysed performing separate comparisons in subpopulations with different ranges of AFC, i.e. < 4, 4-6 and 7-10. Major differences between the two regimens were observed in women with AFC < 4. In this subpopulation, not only was the clinical pregnancies per started cycle higher in the r-FSH/r-LH group (10.2 vs. 1.5%, P < 0.01), but also implantation was significantly higher (13.0 vs. 2.8%, P < 0.02).
Conclusions: A r-FSH/r-LH regimen appears to be beneficial for the treatment of women with extremely poor ovarian reserve. It should be considered however that, being retrospective, this study is affected by obvious limitations, such as post-treatment patient selection criteria and absence of randomisation.
Keywords: FSH; IVF; LH; Ovarian reserve; Ovarian stimulation; Poor responders; Pregnancy; hMG.
Conflict of interest statement
The study was approved by the competent ethical committee (San Gerardo Hospital, Monza, Italy). Written informed consent was obtained from all couples before starting treatment.
Similar articles
-
A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: a retrospective analysis.Eur J Obstet Gynecol Reprod Biol. 2014 Jan;172:70-3. doi: 10.1016/j.ejogrb.2013.10.027. Epub 2013 Nov 5. Eur J Obstet Gynecol Reprod Biol. 2014. PMID: 24314801
-
Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.Hum Reprod. 2015 May;30(5):1188-95. doi: 10.1093/humrep/dev038. Epub 2015 Mar 3. Hum Reprod. 2015. PMID: 25740882 Clinical Trial.
-
A comparison between r-LH and urinary supplements containing LH activity in patients undergoing the microdose GnRH agonist flare protocol for in-vitro fertilization: a pilot study.Minerva Ginecol. 2016 Aug;68(4):393-9. Epub 2016 Mar 17. Minerva Ginecol. 2016. PMID: 26986651
-
Role of LH and FSH in ovarian function.Mol Cell Endocrinol. 2000 Mar 30;161(1-2):25-30. doi: 10.1016/s0303-7207(99)00219-1. Mol Cell Endocrinol. 2000. PMID: 10773387 Review.
-
The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis.Fertil Steril. 2012 May;97(5):1108-14.e1. doi: 10.1016/j.fertnstert.2012.01.130. Epub 2012 Feb 24. Fertil Steril. 2012. PMID: 22365075 Review.
Cited by
-
Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study.J Hum Reprod Sci. 2023 Apr-Jun;16(2):148-155. doi: 10.4103/jhrs.jhrs_37_23. Epub 2023 Jun 30. J Hum Reprod Sci. 2023. PMID: 37547084 Free PMC article.
-
Dosing Characteristics of Recombinant Human Luteinizing Hormone or Human Menopausal Gonadotrophin-Derived LH Activity in Patients Undergoing Ovarian Stimulation: A German Fertility Database Study.Gynecol Obstet Invest. 2023;88(4):214-225. doi: 10.1159/000530360. Epub 2023 Jun 27. Gynecol Obstet Invest. 2023. PMID: 37369184 Free PMC article.
-
A retrospective, matched case-control study of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol.Front Endocrinol (Lausanne). 2022 Aug 15;13:931756. doi: 10.3389/fendo.2022.931756. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36046790 Free PMC article.
-
Luteinizing hormone supplementation in women with hypogonadotropic hypogonadism seeking fertility care: Insights from a narrative review.Front Endocrinol (Lausanne). 2022 Aug 1;13:907249. doi: 10.3389/fendo.2022.907249. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35979440 Free PMC article. Review.
-
Ovarian Follicular Growth through Intermittent Vaginal Gonadotropin Administration in Diminished Ovarian Reserve Women.Pharmaceutics. 2022 Apr 15;14(4):869. doi: 10.3390/pharmaceutics14040869. Pharmaceutics. 2022. PMID: 35456706 Free PMC article.
References
-
- Fatemi HM, Popovic-Todorovic B, Humaidan P, Kol S, Banker M, Devroey P, et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol. Fertil Steril. 2014;101:1008–1011. doi: 10.1016/j.fertnstert.2014.01.019. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
